Tag: T-DM1
Catalent’s SMARTag® ADC Stands Out in the Crowd of HER2-targeted Conjugates
The steadily growing number of HER2-targeted antibody-drug conjugates (ADCs) in preclinical development is a testament to the success of the original anti-HER2 ADC, ado-trastuzumab...
Ado-trastuzumab emtansine Approved for the Treatment of Early Breast Cancer
In early May 2019, the United States Food and Drug Administration (FDA) approved ado-trastuzumab emtansine (Kadcyla®, Genentech/Roche; T-DM1) for the adjuvant treatment of patients...
DS-8201 Receives SAKIGAKE Designation for Gastric Cancer from Japan’s Ministry of...
DS-8201, an investigational HER2-targeting antibody-drug conjugate or ADC being developed by Daiichi Sankyo, has received SAKIGAKE Designation for the treatment of HER2-positive advanced gastric...
2017 San Antonio Breast Cancer Symposium will Highlight Several Antibody-Drug Conjugates...
This year’s San Antonio Breast Cancer Symposium (SABCS) is taking place on December 5-9th, 2017, and it is expected to bring in a broad...
Antibody-Drug Conjugates at the 59th American Society of Hematology Annual...
This year, in Atlanta, the South's largest and most vibrant city, the 59th annual meeting and exposition of the American Society of Hematology, to...
U.S. FDA Accepts Investigational New Drug Application for Mersana’s Lead Antibody-Drug...
The U.S. Food and Drug Administration (FDA) cleared Mersana Therapeutics’ Investigational New Drug (IND) application to begin Phase I clinical trials for its lead...
Phase I Study Shows Daichi Sankyo’s Anti-HER2 Antibody-drug Conjugate DS-8201a to...
Safety and preliminary efficacy data from a phase I study of DS-8201a (Daiichi Sankyo Company), a novel investigational HER2-targeting antibody drug conjugate or ADC,...
Biparatopic HER2-targeting Antibody-drug Conjugate Demonstrates Potent Antitumor Activity
HER2-targeted therapies have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of breast cancer. Being overexposed in 20-25% of human breast cancers...
Initial Results from Phase I Trial with anti-HER2 ADC SYD985 Shows...
Researchers working for Dutch pharmaceutical company Synthon Biopharmaceuticals based in Nijmegen, The Netherlands, report positive initial results from the dose-escalation part of its ongoing first-in-human trial...
Looking Ahead to 2020: Global Antibody-drug Market Prediction
Cytotoxic drugs used in the treatment of solid tumors and hematological malignancies have, over the last 50 years, changed the natural progression of these...
